Previous 10 | Next 10 |
BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
2024-02-07 10:00:01 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
2024-02-07 08:22:27 ET Losers: Snap ( SNAP ) -30% after Q4 earnings release . Triumph Group ( TGI ) -19% after Q3 earnings release . MeridianLink ( MLNK ) -14% announces secondary offering of 6.5M shares . fuboTV ( FUBO ) -14% . ...
BOSTON and ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, I...
2024-01-26 12:32:20 ET Gainers: Corbus Pharmaceuticals Holdings ( CRBP ) +300% . Aclarion ( ACON ) +66% . Panbela Therapeutics ( PBLA ) +36% . Inspire Veterinary Partners ( IVP ) +36% . Rail Vision Ltd ( RVSN ) +34% . Appfoli...
2024-01-17 03:01:33 ET More on Inhibikase Therapeutics Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Financial information for Inhibikase Therapeutics For further details see: Inhibikas...
BOSTON and ATLANTA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and...
2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist a...
A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...
A look at the top 10 most actives in the United States Moolec Science SA (MLEC) rose 85.7% to $2.6 on volume of 50,077,650 shares SuperCom Ltd. (SPCB) rose 46.0% to $0.3212 on volume of 37,315,721 shares AGBA Group Holding Limited (AGBA) rose 35.2% to $1.69 on volume of 26,672,582 shares ...